Cubist Systematic Strategies, LLC Denali Therapeutics Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $1,247 - $1,784	77 New	77 $1,000
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $1.52 Million - $2.15 Million	-65,164 Reduced 70.98%	26,642 $786,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $1.91 Million - $2.84 Million	86,966 Added 1796.82%	91,806 $2.12 Million
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $880,406 - $1.14 Million	-33,501 Reduced 87.38%	4,840 $134,000
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $871,631 - $1.29 Million	-33,563 Reduced 46.68%	38,341 $1.18 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $1.16 Million - $1.96 Million	55,735 Added 344.7%	71,904 $2.12 Million
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $240,787 - $392,482	8,303 Added 105.56%	16,169 $520,000
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $74,106 - $95,734	-1,740 Reduced 18.11%	7,866 $351,000
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $264,797 - $427,292	-5,462 Reduced 36.25%	9,606 $485,000
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $3.45 Million - $5.38 Million	-68,573 Reduced 81.98%	15,068 $1.18 Million
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $3.35 Million - $5.07 Million	62,192 Added 289.95%	83,641 $4.78 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $2.44 Million - $6.19 Million	-66,120 Reduced 75.51%	21,449 $1.8 Million
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $1.55 Million - $2.6 Million	66,979 Added 325.3%	87,569 $3.14 Million
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $46,573 - $83,837	-2,909 Reduced 12.38%	20,590 $498,000
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $333,685 - $657,502	23,499 New	23,499 $411,000
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $385,540 - $586,437	-20,840 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.99 - $24.65 $374,911 - $513,705	20,840 New	20,840 $484,000
Q1 2018 May 15, 2018	SELL	$15.36 - $24.8 $180,864 - $292,020	-11,775 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$15.04 - $21.45 $177,096 - $252,573	11,775	11,775 $184,000

Others Institutions Holding DNLI

# of Institutions

227

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

Baillie Gifford & CO

13.3M
Shares

$287 Million
0.3% of portfolio
Black Rock Inc. New York, NY

13.2M
Shares

$283 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

11.2M
Shares

$240 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

10.7M
Shares

$231 Million
0.06% of portfolio
Capital Research Global Investors Los Angeles, CA

7.91M
Shares

$170 Million
0.05% of portfolio

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account